Working… Menu

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia (PONATINIB-AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02428543
Recruitment Status : Active, not recruiting
First Posted : April 29, 2015
Last Update Posted : August 10, 2020
Information provided by (Responsible Party):
Philippe ROUSSELOT, Versailles Hospital

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2023